Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04290806

Registry Platform Gastric/Esophageal Cancer (SAPHIR)

The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Esophageal Squamous Cell Carcinoma Adenocarcinoma Of Esophagus Carcinoma Carcinoma, Squamous Cell Digestive System Diseases Digestive System Neoplasms Esophageal Adenocarcinoma Esophageal Diseases Esophageal Neoplasms Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Gastrointestinal Diseases Gastrointestinal Neoplasms Head and Neck Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Neoplasms, Squamous Cell

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

SAPHIR is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of metastatic esophageal, gastric or gastroesophageal junction Cancer in Germany. The registry will follow patients for up to two years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.

Health-related quality of life (HRQoL) will be evaluated for up to two years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically proven stage IV (metastatic) ESCC, EAC, GAC or GEJAC
  • Planned palliative systemic first-line therapy
  • Age >= 18 years
  • Signed informed consent (IC)
  • Patients answering questionnaires: IC before first therapy cycle
  • Patients not answering questionnaires: IC latest 4 weeks after start of first therapy cycle

Exclusion criteria

  • No systemic therapy for ESCC, EAC, GAC or GEJAC

Treatment and study plan

Routine care as per site standard

Other

Physician's choice according to patient's needs. Routine care as per site standard.

Primary outcomes

  1. Course of treatment (treatment reality)

    Time frame: 2 years per patient

    Documentation of anamnestic data and therapy sequences

Study contacts

Contact information is provided by the study sponsor or research team.

Adrian Binninger

CONTACT

[email protected]

+49 761 152 42 - 0

Sponsors and collaborators

Lead sponsor

iOMEDICO AG

Industry

Registry information

Official study title

Clinical Research Platform For Molecular Testing, Treatment, Quality Of Life And Outcome Of Patients With Esophageal, Gastric Or Gastroesophageal Junction Cancer Requiring Palliative Systemic Therapy

Acronym: SAPHIR

Important dates

Study start
2019
Primary completion
2028
Study completion
2028
First posted
Mar 2, 2020
Registry last updated
Jan 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.